Wiebe Surgery for TLE
A Randomized, Controlled Trial of Surgery for Temporal-Lobe Epilepsy
Year of Publication: 2001
Authors: Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group
Journal: New England Journal of Medicine
Citation: Wiebe S et al. N Engl J Med. 2001;345(5):311-318. DOI: 10.1056/NEJM200108023450501
Link: https://www.nejm.org/doi/10.1056/NEJM200108023450501
PDF: https://www.nejm.org/doi/pdf/10.1056/NEJM200108023450501
PDF: Clinical Question
Is anterior temporal lobectomy superior to optimized medical therapy for achieving seizure freedom in patients with drug-resistant temporal lobe epilepsy?
Study Overview
Objective
To compare anterior temporal lobectomy with optimized medical therapy in drug-resistant temporal lobe epilepsy.
Study Summary
- In the first RCT of epilepsy surgery, 58% of surgical patients were free of seizures impairing awareness at 1 year vs 8% with medical therapy (p<0.001; NNT 2)
- Complete seizure freedom (including auras) was 38% (surgery) vs 3% (medical)
- Quality of life (QOLIE-89) was significantly higher after surgery; surgical complications occurred in ~10% and 1 medical patient died of SUDEP
Intervention
Standardized anterior temporal lobectomy vs optimized medical (AED) therapy; N=80
Patients per Arm
Surgery: 40, Medical: 40
Bottom Line
In this first-ever RCT of epilepsy surgery, anterior temporal lobectomy was overwhelmingly superior to medical therapy, with 58% vs 8% achieving freedom from seizures impairing awareness at 1 year (p<0.001, NNT=2). Surgery also significantly improved quality of life, disability scores, and complete seizure freedom (38% vs 3%). Surgical complications occurred in 10% (verbal memory decline, visual field cut, wound infection) with no operative mortality.
Major Points
- Surgery superior: seizure-free at 1 year 58% vs 8% (P<0.001). NNT=2.
- Quality of life (QOLIE-89) significantly better: surgery 75.7 vs medical 65.2 (P<0.001).
- 80 patients randomized (40 surgery, 40 medical). Single center (London, Canada).
- Surgery: anterior temporal lobectomy (standardized). Medical: optimized AED management.
- Verbal memory decline in dominant surgery: 20% had significant decline on neuropsych testing.
- 4 surgical complications: 1 wound infection, 1 CSF leak, 1 visual field defect, 1 depression.
- Only RCT of epilepsy surgery vs medical management — remains definitive evidence.
- Landmark trial establishing Class I evidence for surgery in drug-resistant TLE.
- Published NEJM 2001. Led to guideline recommendations for early surgical referral.
- Mean duration of epilepsy: ~20 years — argues for earlier referral than current practice.
Design
Study Type: Prospective, randomized, controlled, parallel-group trial with blinded outcome assessment
Randomization: 1
Blinding: Outcome assessors blinded; patients and surgeons unblinded
Enrollment Period: March 1996 to February 2000
Follow-up Duration: 1 year
Centers: 1
Countries: Canada
Sample Size: 80
Analysis: Intention-to-treat; London Health Sciences Centre, University of Western Ontario
Inclusion Criteria
- Age 16-69 years.
- Drug-resistant temporal lobe epilepsy (failed ≥2 adequate AED trials).
- Seizures >1 year duration.
- Concordant EEG and MRI findings localizing to temporal lobe.
- Candidate for anterior temporal lobectomy.
Exclusion Criteria
- Extratemporal epilepsy.
- Prior resective epilepsy surgery.
- Progressive neurological disease.
- Contraindication to surgery.
Baseline Characteristics
| Characteristic | Surgery | Medical Therapy |
|---|---|---|
| N | 40 | 40 |
| Mean age | ~35 years | ~35 years |
| MRI finding | Majority mesial temporal sclerosis | Majority mesial temporal sclerosis |
| Mean epilepsy duration | ~20 years | ~20 years |
Arms
| Field | Anterior Temporal Lobectomy | Control |
|---|---|---|
| Intervention | Standardized anterior temporal lobectomy performed by a single surgical team within study protocol | AED therapy optimized by treating epileptologists for 1 year; after 1 year, patients offered surgical evaluation/surgery |
| Duration | 1 year follow-up | 1 year follow-up |
Outcomes
| Outcome | Type | Control | Intervention | HR / OR / RR | P-value |
|---|---|---|---|---|---|
| Freedom from seizures impairing awareness at 1 year | Primary | Medical: 3/40 (8%) seizure-free | Surgery: 23/40 (58%) seizure-free | 2 | <0.001 |
| Complete seizure freedom (including auras) | Result: Surgery 38% vs Medical 3% | Secondary | ||||
| Quality of life (QOLIE-89) | Result: Significantly better in surgical group (p<0.001) | Secondary | ||||
| Disability | Result: Improved significantly in surgical group | Secondary | ||||
| Death | Result: 1 death in medical group (SUDEP); 0 in surgical group | Secondary | ||||
| Any surgical complication | Adverse | N/A | 4/40 (10%) | ||
| Verbal memory decline | Adverse | N/A | Reported in surgical group | ||
| Superior quadrantanopia | Adverse | N/A | Reported in surgical group | ||
| Wound infection/CSF leak | Adverse | N/A | Reported in surgical group | ||
Subgroup Analysis
Benefit consistent across MRI-positive (mesial temporal sclerosis) and MRI-negative cases, though numbers small
Criticisms
- Single-center study: may not generalize to all surgical centers and teams
- Short follow-up (1 year only): does not capture long-term seizure recurrence (30-50% by 10 years in observational data)
- Small sample size (n=80) limits power for subgroup analyses
- Waiting-list control design: medical group knew they would receive surgery later, potential nocebo effect
- Cannot blind patients or surgeons: expectation bias possible
- Predominantly mesial temporal sclerosis population -- may not generalize to other TLE pathologies
- Limited ethnic and socioeconomic diversity
Funding
Canadian Institutes of Health Research (formerly Medical Research Council of Canada) and Ontario Ministry of Health (non-industry)
Based on: Wiebe Surgery for TLE (New England Journal of Medicine, 2001)
Authors: Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group
Citation: Wiebe S et al. N Engl J Med. 2001;345(5):311-318. DOI: 10.1056/NEJM200108023450501
Content summarized and formatted by NeuroTrials.ai.